These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 4727450)

  • 21. The metabolic spectrum of halofenate.
    Ryan JR
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):239-43. PubMed ID: 51838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Problems of long-term treatment of hyperlipoproteinemia with clofibrinic acid].
    Hanefeld M; Schulze J; Fritz T; Kemmer C
    Z Gesamte Inn Med; 1973 May; 28(10):Suppl 10:160 c. PubMed ID: 4200340
    [No Abstract]   [Full Text] [Related]  

  • 23. Proceedings: Potentiating of lipid lowering activity of clofibrate by combining with low doses of 3-pyridylcarbinol in rats.
    Simane Z; Nowak H
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(Suppl):suppl 282:R94. PubMed ID: 4276652
    [No Abstract]   [Full Text] [Related]  

  • 24. [Relation of blood pressure to the body weight index and to metabolic parameters].
    Haller H; Leonhardt W; Moser W; Hanefeld M
    Z Gesamte Inn Med; 1973 Jul; 28(14):Suppl:211-3. PubMed ID: 4728091
    [No Abstract]   [Full Text] [Related]  

  • 25. [The effect of long-term plasmapheresis on the composition of blood. III. Changes in the concentration of total, direct and indirect bilirubin, alkaline phosphatase, serum transaminases (SGOT, SGPT). total lipids, triglycerides and cholesterol].
    Grgicević D
    Bilt Hematol Transfuz; 1983; 11(2-3):39-50. PubMed ID: 6680299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
    Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
    Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of chenodesoxycholic acid on serum lipids and enzymes (transaminases) in patients with biliary lithiasis].
    Bataller Sifre R; Pascual Bataller E; Rosique Martínez A; Miralles Espi MC
    Rev Esp Enferm Apar Dig; 1982 Feb; 61(2):141-4. PubMed ID: 7089362
    [No Abstract]   [Full Text] [Related]  

  • 28. [Why take fasting blood samples for laboratory diagnosis? Behavior of various laboratory parameters in postprandial blood samples].
    Bloedner CD
    Fortschr Med; 1984 Nov; 102(44):1123-7. PubMed ID: 6151934
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of ethofibrate [2-(nicotinoyloxy)ethyl-p-chlorophenoxyisobutyrate] on lipid metabolism. I. Effect on blood lipids in normal and hyperlipemic rats].
    Maroto ML; Priego JG; Piña M; Catalán RE
    Arch Farmacol Toxicol; 1978 Apr; 4(1):25-7. PubMed ID: 697396
    [No Abstract]   [Full Text] [Related]  

  • 30. Reduction of serum lipids in familial hyperlipidemias by a tetralin derivative.
    Oriente P; Motolese M; Cerqua R; Mancini M
    Int Z Klin Pharmakol Ther Toxikol; 1969 Oct; 2(4):348-53. PubMed ID: 4903988
    [No Abstract]   [Full Text] [Related]  

  • 31. [Contribution to the study of blood uric acid in normal individuals: correlation between blood cholesterol, triglycerides, total lipids, sugar and free fatty acids].
    Godoy M; Giannini SD; Diament J; Forti N; Thomè O; Papaléo Neto M; Stellin JA; Coelho LT; Paula e Silva P
    Rev Hosp Clin Fac Med Sao Paulo; 1971; 26(1):15-22. PubMed ID: 5553898
    [No Abstract]   [Full Text] [Related]  

  • 32. [Liver lesions and lipid metabolism. I. Lipid, bilirubin and enzyme activities in plasma in experimental cholestasis in rats].
    Kattermann R; Wörner R; Brunner G; Hunstein W
    Acta Hepatosplenol; 1970; 17(1):36-47. PubMed ID: 5437102
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of the effects of halofenate (MK-185) and clofibrate on plasma lipid and uric acid concentration in hyperlipoproteinemic patients.
    Lisch HJ; Patsch J; Sailer S; Braunsteiner H
    Atherosclerosis; 1975; 21(3):391-9. PubMed ID: 1148032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative clinico-pharmacological studies on the lipid lowering effect of EMO 100 and clofibrate].
    Leopold G; Simane Z; Stoll KD; Breuer J
    Med Welt; 1975 Aug; 6(35):1542-4. PubMed ID: 1177741
    [No Abstract]   [Full Text] [Related]  

  • 35. Hypolipemic effect of water extracts of Picrorrhiza rhizoma in PX-407 induced hyperlipemic ICR mouse model with hepatoprotective effects: a prevention study.
    Lee HS; Ahn HC; Ku SK
    J Ethnopharmacol; 2006 May; 105(3):380-6. PubMed ID: 16406704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EFFECT OF ATROMID ON PLASMA LIPIDS AND LIPROPROTEINS IN SUBJECTS WITH HYPERLIPOPROTEINEMIA. (A PRELIMINARY REPORT).
    CARLSON LA; HOEGSTEDT B; OROE L
    J Atheroscler Res; 1963; 3():467-74. PubMed ID: 14100887
    [No Abstract]   [Full Text] [Related]  

  • 37. Blood constituent changes in fasted ponies.
    Baetz AL; Pearson JE
    Am J Vet Res; 1972 Oct; 33(10):1941-6. PubMed ID: 5074699
    [No Abstract]   [Full Text] [Related]  

  • 38. Alcoholic hyperlipaemia.
    Gebbie T; Prior IA
    Med J Aust; 1967 Oct; 2(17):769-72. PubMed ID: 6061028
    [No Abstract]   [Full Text] [Related]  

  • 39. [Influence of a combined treatment using clofibrate and persantin persantinat on increased serum lipid levels].
    Hammerl H; Nebosis G; Pichler O; Studlar M
    Med Welt; 1973 Mar; 24(12):468-70. PubMed ID: 4700881
    [No Abstract]   [Full Text] [Related]  

  • 40. [Modification of serum uric acid concentration under long-term therapy with the lipid-regulating drug Duolip].
    Scherhag R
    Fortschr Med; 1983 Sep; 101(36):1635-7. PubMed ID: 6629296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.